Mode
Text Size
Log in / Sign up

Clinical Trial Search

Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.

Phase
Intervention
Population
Results posted

30 closest matches · ranked by relevance

Phase 3 N=614 Efficacy and Safety of Cefepime/Nacubactam or Aztreonam/Nacubactam Compared to Imipenem/Cilastatin in Subjects With Complicated Urinary Tract Infections or Acute Uncomplicated Pyelonephritis

Complicated Urinary Tract Infection · Acute Pyelonephritis · cUTI
Primary: Proportion of Patients Who Achieve Composite Clinical and Microbiological Success at TOC (Test of Cure Visit) in the Microbiological Modified Intent-to-Treat (m-MITT)…
Meiji Seika Pharma Co., Ltd. Results Nov 2025 2.5% serious AE View details

Phase 3 N=1,068 Study Comparing the Safety and Efficacy of Intravenous CXA-201 and Intravenous Levofloxacin in Complicated Urinary Tract Infection, Including Pyelonephritis

Complicated Urinary Tract Infection · Pyelonephritis
Primary: The Percentage of Subjects Who Have Both a Per-subject Microbiological Outcome of Eradication and a Clinical Outcome of Cure at the Test of Cure (TOC) Visit in the…
Cubist Pharmaceuticals LLC, a subsidiary of… Results Jan 2015 3.1% serious AE View details

Phase 3 N=1,690 A Study of Oral Tebipenem Pivoxil Hydrobromide (TBP-PI-HBr) Compared to Intravenous Imipenem-cilastatin in Participants With Complicated Urinary Tract Infection (cUTI) or Acute Pyelonephritis (AP)

Urinary Tract Infection · Acute Pyelonephritis
Primary: Number of Participants With Overall Response at the Test-of-Cure (TOC) Visit in the Microbiological Intent-to-Treat (Micro-ITT) Population — 261; 291; 171; 179…
Spero Therapeutics Results Mar 2026 3.0% serious AE View details

Phase 3 N=1,372 Study to Assess the Efficacy, Safety and Pharmacokinetics of Orally Administered Tebipenem Pivoxil Hydrobromide (SPR994) Compared to Intravenous Ertapenem in Participants With Complicated Urinary Tract Infection (cUTI) or Acute Pyelonephritis (AP)

Complicated Urinary Tract Infection · Acute Pyelonephritis
Primary: Overall Response (Combined Clinical Cure and Microbiological Eradication) at Test-of-Cure (TOC) in Micro Intent-to-Treat Population — 264; 258 Participants
Spero Therapeutics Results Jul 2022 1.9% serious AE View details